- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03839953
Exercise Rehabilitation for Patients With Critical Limb Ischemia After Revascularization
Exercise Rehabilitation for Critical Limb Ischemia Patients After Revascularization: Pilot Randomized Controlled Trial Assessing Functional Capacity and Quality of Life After a 12-week Rehabilitation Program Versus Best Medical Therapy
Study Overview
Status
Intervention / Treatment
Detailed Description
Background: Peripheral arterial disease (PAD) refers to narrowing and occlusion of arteries supplying oxygenated blood to non-coronary and non-intracranial circulatory systems. This term is typically used to describe disease in the legs though it also affects upper extremities, renal and mesenteric vessels. Symptomatic patients typically experience leg pain with walking or physical activity which is referred to as intermittent claudication (IC). In more advanced chronic disease states with severely compromised blood flow to the tissues, patients may have leg pain at rest or even non healing wounds that can lead to tissue loss which is defined as critical limb ischemia (CLI).
Risk factor management is critical for PAD patients with the goal of improving symptoms and preventing disease progression. This includes smoking cessation as well as appropriate management for hypertension, dyslipidemia and diabetes. Antiplatelet therapy should be initiated in symptomatic patient or when other risk factors are present. Exercise interventions should be encouraged in all patients with PAD. In patients who have progressed to critical limb ischemia, treatment goals are to relieve pain, heal wounds and prevent limb loss. In addition to risk factor management and medical therapy, these patients require revascularization procedures. Depending on the extent and location of disease, the techniques used may be endovascular/interventional (minimally invasive), surgical, or a hybrid combination of the two.
There has been minimal research examining exercise rehabilitation after revascularization. There are no studies that have focused on exercise rehabilitation exclusively in patients with CLI.
Purpose/Objectives: The aim of this study is to develop a better understanding of the role for supervised exercise rehabilitation programs (SEP) in PAD-CLI patients after revascularization. This pilot study will assess the feasibility for expanding this research to a larger randomized controlled trial.
Study Design:
This is a two-phase, single-center, non-blinded randomized controlled trial.
Objectives:
In phase 1, the investigators will assess feasibility. Specifically, the investigators will assess rate of enrollment, barriers to participation and any methodological challenges that may require changes. If phase 1 of this study shows reasonable rates of enrollment and no methodological challenges, we will proceed to phase 2.
Key objectives for phase 2 are as follows:
- The primary objective is to show how SEP affects functional capacity and quality of life in patients with PAD-CLI after revascularization.
- The secondary objective is to show how SEP affects the rate of major adverse limb events (MALE) and improve survival in patients with PAD-CLI after revascularization.
Hypotheses: 1) PAD-CLI patients who have undergone revascularization will have a greater improvement in functional capacity and quality of life compared with patients treated with best medical therapy alone.
2) PAD-CLI patients who have undergone revascularization will have fewer MALE and improved survival compared with patients treated with best medical therapy alone.
Methodology: Patients included in the study will be identified in the vascular surgery outpatient clinic or through emergency department as requiring revascularization secondary to critical limb ischemia. Patients will be approached regarding study participation prior to the revascularization procedure. After eligibility is confirmed and patients have signed informed consent, patients will be randomized to one of two groups:
- Best Medical Therapy (BMT): Appropriate risk factor management, encouragement to mobilize.
- Supervised Exercise Program (SEP): consist of BMT plus a supervised exercise program.
Patients will undergo evaluation of functional capacity assessment using a graded treadmill test at the outset of the study and after 12 weeks of either BMP or SEP. The investigators will also administer a validated quality of life (QoL) questionnaire to the two different groups at the outset and completion of the study. Patients will be followed annually to monitor for MALE and survival.
Statistics: Normally distributed data will be presented as mean ± SD. Results at baseline and 12 weeks will be compared using a paired t-test. For data that is not normally distributed, comparisons will be performed using a non-parametric Mann-Whitney test. Comparisons will be accepted as statistically significant at 95% confidence level (p≤0.05). STATA software will be used for statistical analysis.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T1Y 6J4
- Peter Lougheed Center, Alberta Health Services, University of Calgary
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ambulating prior to procedure
- Living independently prior to procedure
- Available to attend all SEP and follow-up appointments
- PAD Fontaine class III and IV (rest pain and tissue loss)
- Entry with consent of vascular surgeon
- Ischemia secondary to TASC A-D lesions identified on imaging (CTA or angiogram)
- Able to understand and sign informed consent
- >18 years of age
Exclusion Criteria:
- Confined to wheelchair
- Patients with exercise tolerance limitations due to other co-morbidities such as cardiorespiratory, musculoskeletal, or peripheral neuropathy. (NYHA class III and IV)
- PAD Fontaine class I and II (asymptomatic, claudication)
- Patients with ongoing tissue loss that limits ambulation
- Patient with previous revascularization procedures
- Patients undergoing revascularization for acute limb ischemia events
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Best Medical Therapy
After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist.
This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
|
After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist.
This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
|
|
Experimental: Supervised Exercise Program
Patients will receive best medical therapy plus participation in a 12-week supervised exercise program.
|
This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of enrollment
Time Frame: 3 months
|
A minimum of 3 patients per month should be enrolled
|
3 months
|
|
Functional Capacity
Time Frame: Three months
|
Functional capacity will be evaluated by a six-minute walk test
|
Three months
|
|
Quality of Life assessed by VascuQuol questionnaire
Time Frame: Three months
|
Questionnaire with 25 items validated for patients with peripheral arterial disease
|
Three months
|
|
Health status assess by SF-36
Time Frame: Three months
|
36-item self-reported survey that provides a measure of patient health
|
Three months
|
|
Barriers or experiences with physical activity
Time Frame: Three months
|
We will conduct a 30-minute interview to gain better understanding of patient experiences with exercise rehabilitation.
|
Three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major adverse limb events (MALE)
Time Frame: Five years
|
Clinical deterioration or condition requiring surgical interventions
|
Five years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Randy D Moore, MD, University of Calgary
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REB17-730
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
Marissa JarosinskiTerminatedPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
OrbusNeichEucatech AG; Centre Européen de Recherche CardiovasculaireRecruitingPeripheral Arterial Disease | Peripheral Arterial Occlusive DiseaseSpain, Singapore, Belgium, Germany
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Wroclaw Medical UniversityPoznan University of Medical Sciences; Military Institute of Medicine National...RecruitingPeripheral Arterial Disease(PAD)Poland
-
Louisiana State University Health Sciences Center...Not yet recruitingPeripheral Arterial Disease(PAD)United States
-
BayerCompleted
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
Clinical Trials on Best Medical Therapy
-
Capital Medical UniversityNot yet recruitingIschemic Stroke | Basilar Artery Occlusion | Large Core InfarctChina
-
Singapore General HospitalSingapore College of Traditional Chinese MedicineUnknown
-
Imperial College LondonCompleted
-
Rennes University HospitalRecruitingHypertrophic Cardiomyopathy (HCM)France
-
Royal College of Surgeons, IrelandRecruitingInflammatory Bowel DiseasesIreland
-
First Affiliated Hospital of Wannan Medical CollegeThe First Affiliated Hospital of Anhui Medical University; Taihe Hospital; Linyi... and other collaboratorsRecruitingRescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular OcclusionStroke, Ischemic | Cerebrovascular; Disorder, OcclusiveChina
-
Zhongming QiuXingguo County People's HospitalRecruitingStroke HemorrhagicChina
-
Philips Portuguesa S.A.RecruitingStroke | Sleep ApneaPortugal
-
Seoul National University HospitalSeoul National University Bundang HospitalTerminated
-
Sir Run Run Shaw HospitalRecruitingVascular Diseases | Cerebrovascular Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Brain Infarction | Stroke, AcuteChina